Randomised Controlled Trial on Adjuvant Transarterial Chemoembolisation After Curative Hepatectomy for Hepatocellular Carcinoma
Liver resection is the mainstay of curative treatment for hepatocellular carcinoma (HCC).
However, recurrence is common after surgery and most occurs in the liver. Transarterial
chemoembolisation (TACE) is an effective palliative treatment for HCC. It involves the
infusion of chemotherapeutic agent admixed with iodised oil followed by embolisation of the
hepatic arterial flow using small particles. This procedures allows application of smaller
dose of chemotherapy concentrated to the liver and thus is well tolerated with minimal side
effects. We conduct a randomised controlled trial evaluating the efficacy of using TACE
after hepatectomy in HCC patients.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
1-year recurrence rate
The 1-year recurrence rate after hepatectomy in both arms of study were compared
1-year after hepatectomy
Yue Sun Cheung, MBChB
Chinese University of Hong Kong
Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee